Media headlines about Horizon Pharma (NASDAQ:HZNP) have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Horizon Pharma earned a news impact score of 0.13 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.0395119427026 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Horizon Pharma Sees Unusually Large Options Volume (HZNP) (americanbankingnews.com)
- Horizon Pharma (HZNP) Upgraded to “Buy” by Mizuho (americanbankingnews.com)
- Volume Moving the Tape -0.32% For Horizon Pharma Ord (HZNP) – SCY News (scynews.com)
- Worthy Analytical Review for Horizon Pharma plc (NASDAQ:HZNP … – The Oracle Examiner (oracleexaminer.com)
- Horizon Pharma (HZNP) Increases Peak Net Sales Guidance, Announces Rheumatology and Orphan Pipeline … – StreetInsider.com (streetinsider.com)
HZNP has been the subject of several analyst reports. Cantor Fitzgerald reissued a “buy” rating and set a $17.00 target price on shares of Horizon Pharma in a research note on Tuesday, September 26th. Jefferies Group reissued a “buy” rating and set a $16.00 target price on shares of Horizon Pharma in a research note on Wednesday, September 27th. Goldman Sachs Group assumed coverage on Horizon Pharma in a research note on Thursday, September 28th. They set a “buy” rating and a $16.00 target price for the company. Cowen reaffirmed a “buy” rating on shares of Horizon Pharma in a report on Thursday, September 28th. Finally, Zacks Investment Research downgraded Horizon Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $19.25.
Horizon Pharma (NASDAQ:HZNP) traded up $0.09 during trading on Friday, hitting $15.18. The stock had a trading volume of 3,326,022 shares, compared to its average volume of 1,820,000. The stock has a market cap of $2,460.00, a P/E ratio of -4.99, a P/E/G ratio of 0.70 and a beta of 1.30. Horizon Pharma has a fifty-two week low of $9.45 and a fifty-two week high of $17.69. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.64 and a quick ratio of 1.52.
Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.04. The firm had revenue of $271.60 million for the quarter, compared to analysts’ expectations of $259.74 million. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The firm’s revenue for the quarter was up 30.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.70 EPS. sell-side analysts forecast that Horizon Pharma will post 0.72 earnings per share for the current year.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.